Drug Delivery in Cancer Report 2017 - Technologies, Markets

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
403
Drug Delivery in Cancer Report 2017 - Technologies, Markets and Companies 2015-2025: Profiles of 232 Companies with 270 Collaborations

Dublin, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering. Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance. Innovative cancer therapies are based on current concepts of molecular biology of cancer. These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. Important methods of immunotherapy in cancer involve use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy. Several innovative methods of drug delivery are used in cancer. These include use of microparticles as carriers of anticancer agents. These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery. Polyethylene glycol (PEG) technology has been used to overcome some of the barriers to anticancer drug delivery. Encapsulating anticancer drugs in liposomes enables targeted drug delivery to tumor tissues and prevents damage to the normal surrounding tissues. Monoclonal antibodies can be used for the delivery of anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to the tumors. Antisense oligonucleotides have been in clinical trials for cancer for some time now. RNAi has also been applied in oncology. Small interfering RNAs (siRNAs) can be targeted to tumors and one example is suppression of H-ras gene expression indicating the potential for application in therapy of ovarian cancer. Cancer gene therapy is a sophisticated form of drug delivery for cancer. Various technologies and companies developing them are described. Nucleic acid-based cancer vaccines are also described. Drug delivery strategies vary according to the type and location of cancer. Role of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical. Biodegradable implants of carmustine are already used in the treatment of malignant brain tumors. The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2015-2025 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described. Profiles of 232 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 270 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 66 tables and 12 figures. Key Topics Covered: Part I: Technologies & Markets Executive Summary 1. Introduction to cancer therapy

2. Innovative treatments for cancer

3. Drug delivery systems for cancer

4. Delivery of Biological Therapies for Cancer

5. Delivery strategies according to cancer type and location

6. Cancer drug delivery markets

7. References Part II: Companies 8. Companies involved in cancer drug delivery For more information about this report visit http://www.researchandmarkets.com/research/gq...elivery_in

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Drug Delivery, Oncology Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Classic vs. Youngtimer Cars: Evolution in Collecting

Updated Category News Views 90

The Collector's Journey: Classic Cars vs. Youngtimers Ever notice how car collecting has its own circles of fame? You're either basking in the glow of a vintage classic or eyeing a youngtimer that’s just catching steam. In this article from HelloNation, Engels Gualdani — the classic car sage of Hilton, NY — helps untangle these categories for us, and it’s a lesson...

Continue Reading
Smart Banner Choices: Decisions Beyond Design

Updated Category News Views 152

Location, Location, Location: Banner Insights Picking a banner isn't just a quick snap decision. You got to think big, and location is a starting line. Adam Norsworthy from Minuteman Press underscores that understanding how and where this piece of publicity will hang matters more than you might guess. Outdoor or indoor isn't just a weather question; it's a matter of...

Continue Reading
PangeAI and Sky Blue Transform Data Center Decisions

Updated Category News Views 80

Just when you thought the incessant trials of picking a prime data center site couldn’t get any more grueling or expensive, enter PangeAI and its brand-new ally, Sky Blue Impact. These tech firms have partnered up to speed up what has traditionally been a sluggish, pricey process. Here’s the deal: PangeAI’s geospatial AI platform lets Sky Blue dodge the usually...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 37

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
Toys"R"Us Rolls Out 160 U.S. Stores, NYC Celebration

Updated Category News Views 146

Rebuilding the Toy Empire After a rough few years, Toys"R"Us is clawing its way back into the hearts—and wallets—of American shoppers. With 160+ new standalone stores popping up like mushrooms after rain, these guys aren't just playing games. This is a strategic move to reestablish their presence in the retail landscape just before the holiday shopping frenzy kicks...

Continue Reading
Nagarro's Earnings Show Stagnant Growth Amid Flat Margins

Updated Category News Views 96

Nagarro's Financial Picture: A Glimpse Live a day in the trading pits and you'll learn to spot when a company is merely treading water. That's the vibe I'm getting from Nagarro's Q3 2026 results. They might label themselves as an AI-native leviathan, but these numbers spell out a story of struggle wrapped in fancy buzzwords. Revenue Uptick or Revenue Hiccup? For the nine...

Continue Reading
APEC Summit 2026: Shenzhen in the Spotlight

Updated Category News Views 58

An International Stage for Shenzhen Alright, folks, here's the deal. We’ve got the 2026 APEC Summit rolling into Shenzhen, perched right there in Guangdong Province, and the world’s eyes are glued to it. Happens November 18–19, and you better believe it’s a magnet for all things global. The China Media Group’s Chinese Global Program Center isn’t missing a...

Continue Reading
Endava Faces Class Action: Investor Reactions and Next Steps

Updated Category News Views 72

Trouble at Endava: Leadership Shakeup and Financial Concerns So, here's the kicker—Endava's got itself into one mighty mess worth chewing over with your morning coffee. When your top brass drops like flies, and you're fumbling your financials, investors start sweating bullets. On October 28, 2026, Endava plc (NYSE: DAVA) confesses to some serious accounting missteps....

Continue Reading
First Horizon's $25M Bet: New Center Transforms Houston

Updated Category News Views 76

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

Continue Reading
Perpetua Reports Q3 2026 Results, Progress on Project

Updated Category News Views 58

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

Continue Reading

Top 5 Most Recently Viewed Articles

Strengthening Heart and Kidney Health Through Collaboration

Updated Category News Views 264

Collaboration for Health Awareness In an exciting development, the American Kidney Fund (AKF) has forged a partnership with the American Heart Association (AHA) as part of their Cardiovascular-Kidney-Metabolic Health Initiative™. This collaboration aims to raise awareness regarding the crucial link between kidney disease and cardiovascular conditions, both of which...

Continue Reading
Kering Faces Challenges Amid Analyst Downgrades and Market Slowdown

Updated Category News Views 106

Kering Faces Challenges Amid Analyst Downgrades and Market Slowdown Kering (EPA: PRTP) has recently experienced a shift in market sentiment as analysts express increasing caution regarding its performance. TD Cowen has notably lowered its price target for Kering to €230 from €260, while sustaining a Hold rating for the stock. The adjustment signals growing concerns...

Continue Reading
Xi Jinping Champions Common Development at G20 Summit

Updated Category News Views 308

Xi Jinping's Vision for Global Cooperation at the G20 Summit Chinese President Xi Jinping recently made headlines during a significant gathering known as the G20 Summit. His participation underscored a strong commitment to fostering global cooperation and development, marking a notable moment in international relations. Advocating for a Unified Approach During his...

Continue Reading
OHA Secures Financing for Onex's Acquisition of Farsound

Updated Category News Views 84

OHA Leads Innovative Financing for Strategic Acquisition In a significant development in the financial world, Oak Hill Advisors (OHA) has taken on the role of Lead Left Arranger for a private unitranche financing aimed at supporting the acquisition of Farsound Aviation Limited by Onex. Farsound stands out in the aerospace engine maintenance, repair, and overhaul (MRO)...

Continue Reading
Zentalis Pharmaceuticals Rebounds After FDA Clearance for Azenosertib

Updated Category News Views 75

Zentalis Pharmaceuticals Advances with Azenosertib Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), located in San Diego, has some exciting updates for its stakeholders. The U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the company's studies involving azenosertib. This is fantastic news, as it enables Zentalis to restart patient enrollment...

Continue Reading